SeraCare Life Sciences’ new precision medicine business unit has introduced its first product, Seraseq Solid Tumor Mutation Mix—I (AF20).
The new biosynthetic reference material has been developed to assess the performance of next generation sequencing (NGS)-based tumor profiling assays.
SeraCare Life Sciences chief scientific officer Russell Garlick said: "SeraCare’s extensive background and experience with the manufacture of quality reference and validation materials under cGMP ISO standards has enabled us to develop the Seraseq Solid Tumor Mutation Mix.
"This technology allows almost unlimited breadth of mutations and can be accurately ‘tuned’ to specific allelic frequencies because we’ve incorporated digital PCR in the manufacturing."
Seraseq Solid Tumor Mutation Mix includes a mixture of mutations in key oncogenes and tumor suppressor genes and will serve as a quality material for translational and disease research testing.
Currently available only for research use, the product also enables laboratories to monitor library preparation, sequencing and variant allele detection under a given set of bioinformatics pipeline or parameters.
Compatible with all major cancer hotspot oncology panels and NGS platforms, the product is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA.
SeraCare Life Sciences CEO Charlie Mamrak said: "The Seraseq Solid Tumor Mutation Mix is just the first of many precision medicine products that SeraCare has in development and we look forward to continuing our commitment to bringing new technologies and tools to our customers."
Image: Seraseq Solid Tumor Mutation Mix-I (AF20). Photo: courtesy of PRNewswire/ SeraCare Life Sciences, Inc.